Poly (ADP-ribose) Polymerase (PARP) Inhibitors

Poly (ADP-ribose) polymerase (PARP) inhibitors are a novel class of pharmaceutical drugs that target the PARP enzymes involved in DNA repair pathways By inhibiting PARP these drugs disrupt the repair mechanisms in cancer cells leading to their selective death This makes PARP inhibitors a promising therapeutic option for the treatment of various cancers particularly those associated with BRCA mutations Our company offers a comprehensive range of highly effective PARP inhibitors that have shown significant clinical benefit in the fight against cancer

Get A Quote

Products Application Supporting Data Resources Related Products

Products

Catalog Number	Chemical Name	CAS #	Price
BC-0019	Phenformin hydrochloride	834-28-6	Online Inquiry
EI-0026	1,5-Isoquinolinediol	5154-02-9	Online Inquiry
EI-0059	4-Hydroxyquinazoline	491-36-1	Online Inquiry
EI-0088	A-966492	934162-61-5	Online Inquiry
EI-0103	ABT-888	912445-05-7	Online Inquiry
EI-0133	AG-014699 phosphate	459868-92-9	Online Inquiry
EI-0136	AG-14361	328543-09-5	Online Inquiry
EI-0284	AZD-2461	1174043-16-3	Online Inquiry
EI-0411	BMN-673	1207456-01-6	Online Inquiry
EI-0765	DPQ	129075-73-6	Online Inquiry
EI-0768	DR2313	284028-90-6	Online Inquiry
EI-1216	Iniparib	160003-66-7	Online Inquiry
EI-1218	INO-1001	3544-24-9	Online Inquiry
EI-1429	ME-0328	1445251-22-8	Online Inquiry
EI-1471	MK-4827	1038915-60-4	Online Inquiry

Application

Poly (ADP-ribose) Polymerase (PARP) inhibitors have a wide range of applications in both research and medicine In the field of research PARP inhibitors are commonly used to study DNA repair mechanisms and the role of PARP enzymes in cellular processes By inhibiting PARP researchers can gain valuable insights into the underlying mechanisms of DNA damage and repair which can contribute to the development of new therapies for cancer and other diseases

In medicine PARP inhibitors are primarily used to treat cancers that have a specific DNA repair defect known as homologous recombination deficiency (HRD) These inhibitors work by blocking the activity of PARP enzymes which are necessary for the repair of single-strand DNA breaks In HRD cancers blocking PARP leads to the accumulation of DNA damage ultimately leading to cell death This targeted approach has shown promise in the treatment of breast ovarian and other types of cancer and is shaping the future of precision medicine

PARP inhibitors also have potential applications beyond cancer treatment They are being investigated for their role in neurodegenerative diseases such as Alzheimer's and Parkinson's as well as in cardiovascular diseases Additionally PARP inhibitors are being explored for their potential to enhance the effectiveness of radiation therapy or chemotherapy in cancer treatment

Overall PARP inhibitors are a versatile tool with significant implications for both research and medicine Their ability to target specific DNA repair pathways has opened up new avenues of treatment and research offering hope for improved outcomes and better understanding of various diseases

Supporting Data

Resources

Please note that all services are for research use only. Not intended for any clinical use.

Get a free quote

If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.